AR 13503
Alternative Names: AR-13503 SR; AR-13503 SR Implant; AR13503; Rho kinase and protein kinase C inhibitor sustained-release implantLatest Information Update: 16 Feb 2023
At a glance
- Originator Aerie Pharmaceuticals
- Developer Alcon
- Class Eye disorder therapies; Small molecules
- Mechanism of Action Protein kinase C inhibitors; Rho-associated kinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Diabetic macular oedema; Wet age-related macular degeneration
Most Recent Events
- 28 Sep 2022 No recent reports of development identified for phase-I development in Diabetic-macular-oedema in USA (Intravitreous, Implant)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Diabetic-macular-oedema(Combination therapy) in USA (Intravitreous, Implant)
- 28 Sep 2022 No recent reports of development identified for phase-I development in Wet age-related macular degeneration in USA (Intravitreous, Implant)